The lipid transcription factor SREBP1 is particularly highly expressed in RA-FLSs, and its genetic ablation or pharmacological inhibition markedly mitigates the pathogenic effects of iron overload both in vitro and in vivo. This evidence concerns the gene SREBF1 and rheumatoid arthritis.